Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101

Ayala Pharmaceuticals Inc AYLA announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations.
The data was presented at the 2021 ESMO Virtual Congress (ESMO21).
Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with a 70% disease control rate (DCR). Partial responses (PR) were observed in 3 patients, stable disease (SD) was observed in 20 patients (61%).
Progressive disease (PD) was observed in 8 patients (24%). In a separate ePoster presentation, Ayala presented new preclinical results evaluating AL101 in combination with approved cancer therapies for dual targeting of ACC tumors.
AL101 in combination demonstrated significant tumor growth inhibition, including regressions, compared to each drug alone, showing significant benefit with dual targeting of Notch and other dysregulated pathways.
ACC is a rare malignancy of the secretory glands, including salivary glands.
Price Action: AYLA shares are down 9.83% at $12.70 during the market session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)